New Publication from NMD4C Investigators: Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond

We are excited to share the publication of a new study “Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond” from Dr. Emily Groulx-Boivin, with NMD4C investigators Dr. Homira Osman, Stacey Lintern, Dr. Maryam Oskoui, Dr. Kathryn Selby, and Dr. Hugh McMillan as co-authors. The article is published in the Canadian Journal of Neurological Sciences, and examines the differences between provincial newborn screening (NBS) programs and the variability of Spinal muscular atrophy (SMA) screening inclusion within these. The article shows there is a regional variability between NBS programs in Canada, which creates inequity in treatment and care and affects potential outcomes of Canadians affected by early-onset childhood diseases, including SMA.

Canadian Newborn Screening Landscape

NBS is a process to identify newborns with potentially disabling conditions for which early detection may allow for treatment initiation to reduce or eliminate disease symptoms 1. While every Canadian province has a NBS program, there is no national governance providing oversight or standardization over which diseases these programs should include. This can lead to inequitable access to treatment and care for Canadian children based on where they are born within the country.

Through this study, the authors conducted a cross-sectional study of all provincial NBS programs in Canada, gathering data from each medical or laboratory director through an online survey. They learned that the number of conditions screened for ranges from as few as 14 to as many as 36, a 2.5-fold difference between the smallest and largest provincial programs. Similarly, in conditions that require genetic testing as opposed to other traditional NBS methods, there is a nine-fold difference in the number of diseases that are currently tested for between the smallest and largest screening programs. Genetic-based testing is required to test for an increasing number of childhood-onset diseases where novel therapies are emerging – including SMA1.

Access to Screening for SMA

As of today, approximately 72% of Canadian newborns are screened for SMA at birth, with six provinces and all three territories providing a NBS program that includes genetic screening for SMA. Although the provinces currently not screening for SMA have indicated their commitment to include this in the near future, differences in the time to receive screening results and the time to initiate therapy means that even in provinces that screen for SMA, delays and inequitable access to timely therapies still exist for children across Canada. These delays are especially devastating for children born with SMA, a disease characterized by rapid and irreversible loss of motor neurons.

The authors recommend that provinces work towards a standardized Canadian NBS program as a next step in order to reduce these inequities and avoid life-altering consequences for children based on the region in which they are born.

Access the full article

The full article is open access, and the full publication is available at:

Network Advocacy for Newborn Screening for Neuromuscular Diseases

The NMD4C is committed to supporting network partner organization Muscular Dystrophy Canada (MDC) in advocating for policy changes to provide SMA screening for all Canadians. From 2020, MDC has been working to understand and address barriers for the implementation of NBS for SMA, and is committed to exploring which other neuromuscular diseases would benefit from inclusion in Canadian screening programs in the future.


Groulx-Boivin E, Osman H, Chakraborty P, Lintern S, Oskoui M, Selby K, Van Caeseele P, Wyatt A, McMillan HJ. Variability in Newborn Screening Across Canada: Spinal Muscular Atrophy and Beyond. Can J Neurol Sci. 2023 Mar 9:1-7. doi: 10.1017/cjn.2023.34. Epub ahead of print. PMID: 36892082.


Read next...

ImPORTND logo with text reading 'new module - skills for patient oriented research'

New Course ‘Skills for Patient Oriented Research’ Added to ImPORTND Training Platform

The third and final module of our patient-oriented research training platform, ImPORTND, is now available! ‘Skills for Patient-Oriented Research’ teaches specific skills to help with patient-oriented research (POR), including how to develop an effective patient engagement plan, share and listen to patient stories, and evaluate project engagement. 

MDC, NMD4C and CSCN fellowships competition is now open

Annual Neuromuscular Postdoctoral Research and Clinical Fellowships Funding Competition Now Open

Our 2024 annual funding competition to award postdoctoral fellowships in neuromuscular disease research, and clinical fellowship awards in neuromuscular medicine and electromyography is now open!


Curriculum Group Wraps up Inaugural Fellows’ Training Series

Our national neuromuscular lecture series launched last August 2022 has just wrapped up! The series consisted of a weekly (38 weeks) virtual Royal College CPD-accredited curriculum for neuromuscular fellows presented by subject-matter experts, developed by the curriculum working group together with the directors of fellowship programs across Canada.  

NMD4C and MDC together offer free training and support for research teams and patients to conduct patient oriented research

ImPORTND – Training for Research Teams and Patient and Family Partners to Conduct Patient-Oriented Research in Neuromuscular Diseases

We are partnering with Muscular Dystrophy Canada (MDC) to offer free training and support services for research teams and patients to empower all members of the research team to conduct research that is informed by, and most meaningful to individuals living with neuromuscular disorders. 

NMD4C awarded grant funding from CIHR-IMHA and funding from MDC for a period of 5 years.

Press Release | Neuromuscular Disease Network for Canada Awarded 5-Year Grant from CIHR-IMHA and Funding from MDC to Strengthen Canadian Neuromuscular Research and Care

The NMD4C has received a network grant from CIHR-IMHA and matched funding from MDC, providing funding of $400 000 per year for five years to strengthen the care, research and treatment of neuromuscular diseases for all Canadians.

Ottawa NMD conference poster

Important Deadlines for Ottawa NMD 2023

The Ottawa International Conference on Neuromuscular Disease and Biology (Ottawa NMD 2023) deadline for discounted early-bird registration and abstract submission is June 30th!